Epigenetics Market by Product, Service, Method, Technique, Application - Global Forecast to 2031

Dublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "Epigenetics Market by Product, Service, Method, Technique, Application - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering.

Epigenetics Market to Reach USD 3.92 Billion by 2031, Driven by Oncology Research, Precision Medicine and Multi-Omics

The epigenetics market is projected to reach USD 3.92 billion by 2031, up from USD 2.22 billion in 2026, registering a compound annual growth rate of 12.0% during the forecast period. Market expansion is being supported by the increasing use of epigenetic analysis in oncology research, precision medicine, drug discovery, biomarker validation and translational studies.

Next-generation sequencing (NGS), PCR and qPCR, mass spectrometry, sonication-based chromatin preparation and methylation arrays are enabling research into DNA methylation, histone modifications, chromatin accessibility, non-coding RNAs and chromatin remodeling. These technologies support cancer diagnostics, therapeutic target identification, disease classification, treatment-response monitoring and research in developmental biology, immunology, neuroscience and metabolic diseases.

Adoption is also increasing through liquid biopsy-based methylation biomarkers, single-cell epigenomics, multi-omics integration and AI-enabled data interpretation. Pharmaceutical and biotechnology companies, academic institutions, clinical laboratories and contract research organizations are expanding their use of epigenetics products and services. Demand for standardized kits, high-quality antibodies, sequencing reagents, enzymes, automated sample-preparation systems and bioinformatics platforms is improving workflow reproducibility and data reliability.

Market growth remains constrained by high sequencing and analysis costs, complex data interpretation, variable antibody performance and difficulties in standardizing epigenetic workflows for broader clinical use. Additional restraints include limited applications of epigenomic data in toxicology, along with data privacy and security concerns. Epigenetic editing and antibody quality also remain important industry challenges.

DNA Methylation Segment Forecast to Register the Highest CAGR

The DNA methylation segment is expected to grow at the highest CAGR during the forecast period, supported by its expanding role in cancer detection, biomarker discovery, disease classification and treatment-response monitoring. DNA methylation assays are used in promoter methylation analysis, gene-silencing studies, epigenetic aging, tumor profiling and liquid biopsy-based diagnostics.

Growing adoption of bisulfite sequencing, methylation-specific PCR, methylation arrays and NGS-based methylation profiling is strengthening demand across pharmaceutical research, clinical laboratories and translational studies. Emerging applications in population screening and epigenetic-based therapeutics are expected to create further opportunities.

Next-Generation Sequencing Holds the Largest Market Share

NGS accounts for the largest share of the epigenetics market because of its ability to generate high-throughput, genome-wide data on epigenetic regulation. The technology is widely used in DNA methylation profiling, ChIP-seq, ATAC-seq, chromatin accessibility studies and single-cell epigenomics.

Strong adoption across oncology research, biomarker discovery, drug development and precision medicine supports the segment's market leadership. Demand is expected to remain strong as researchers pursue deeper epigenomic coverage, scalable analysis and integration with multi-omics workflows. Declining sequencing costs and processing times are also contributing to broader adoption.

US Epigenetics Market Expected to Record the Highest CAGR

The US is projected to grow at the highest CAGR during the forecast period. Growth is supported by the country's concentration of sequencing, molecular biology, diagnostics and bioinformatics companies, as well as its advanced research infrastructure and strong adoption of epigenomic technologies in research and clinical settings.

Epigenetics is increasingly used in the US for oncology, precision medicine, drug discovery, liquid biopsy development and biomarker validation. NGS, PCR and qPCR, methylation arrays, ChIP-seq, ATAC-seq and single-cell epigenomics are used by pharmaceutical companies, biotechnology firms, academic institutions, CROs and clinical laboratories.

Competitive Landscape

Key companies offering epigenetics products and services include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Active Motif, Inc. (US), New England Biolabs (US), QIAGEN (Netherlands), Zymo Research Corporation (US), Revvity (US), Hologic Diagenode (US), F. Hoffmann-La Roche Ltd. (Switzerland), Promega Corporation (US), EpigenTek Group Inc. (US), EpiCypher (US), Fios Genomics (UK), GenomeScan (Netherlands), Creative Biogene (US), BPS Bioscience, Inc. (US), Abnova Corporation (Taiwan), Creative Diagnostics (US), Biomodal (UK), 10x Genomics (US) and Novogene Co., Ltd. (China).

The competitive assessment examines company market shares, growth strategies, product and service portfolios, new product launches, acquisitions, investments and recent industry developments. It also evaluates emerging startups operating across the epigenetics ecosystem.

Research Coverage

The report categorizes the epigenetics market by offering, product, service, technology, method, application, end user and region. Offerings include products and services. Product coverage includes kits and reagents, enzymes, instruments and accessories.

Kits and reagents include antibodies; isolation and extraction kits and reagents; ChIP-sequencing kits and reagents; bisulfite conversion kits and reagents; whole-genome amplification kits and reagents; CUT&RUN and CUT&TAG kits and reagents; 5-hmC and 5-mC analysis kits and reagents; histones; and other kits and reagents. Enzyme coverage includes DNA polymerases, DNA ligases, Tn5 transposase, TET and APOBEC conversion enzymes, protein-modifying enzymes and other enzymes.

Service segments comprise DNA methylation profiling, chromatin profiling, chromatin accessibility profiling, single-cell epigenomics, multi-omics and other services. Technologies covered include NGS, PCR and qPCR, mass spectrometry, sonication and other technologies. Methods include DNA methylation, histone modifications and other approaches.

Application coverage includes oncology, metabolic diseases, immunology, developmental biology, cardiovascular diseases, population screening and other applications. Product end users include academic and research institutes, pharmaceutical and biotechnology companies, hospitals and clinics, and CROs. Service end users include pharmaceutical and biotechnology companies, academic and research institutes, hospitals and clinics, and CROs.

Regional analysis covers North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. The report assesses market drivers, restraints, opportunities and challenges while providing revenue estimates for the overall market and its subsegments.

Research Methodology

• Respondents: supply side, 70%; demand side, 30%.
• Designations: managers, 45%; CXOs and directors, 30%; executives, 25%.
• Regions: North America, 40%; Europe, 25%; Asia Pacific, 25%; Latin America, 5%; Middle East and Africa, 5%.

Market Opportunities and Report Benefits

Key growth drivers include declining sequencing costs and processing times, increased emphasis on population screening programs, advances in epigenetics research and rising demand for epigenetic drugs and epigenetic-based therapeutics. Emerging applications of epigenetics and the integration of multi-omics represent significant market opportunities.

The report provides detailed insights into product development and innovation, including newly launched products and technologies. It identifies attractive regional markets, untapped geographies, recent investments and diversification opportunities. Market leaders and new entrants can use the revenue estimates, subsegment analysis and competitive intelligence to refine market positioning, assess growth strategies and develop go-to-market plans.

Stakeholders can also use the findings to evaluate market dynamics, monitor industry developments and understand the products, services and strategies of leading companies, including Thermo Fisher Scientific Inc., Merck KGaA, Illumina, Inc., PacBio, Danaher Corporation, Bio-Rad Laboratories, Inc., Active Motif, Inc., New England Biolabs, QIAGEN, Zymo Research Corporation and Revvity.

Key Attributes:

Key Topics Covered:

MARKET DYNAMICS

Drivers

• Declining sequencing costs and time
• Growing emphasis on population-scale screening initiatives
• Technological advancements in epigenetics research
• Rising demand for epigenetic drugs and epigenetic-based therapeutics

Challenges

• Restraints
  • Limited applications of epigenomic data in toxicology
  • Data privacy concerns and security issues
• Challenges
  • Concerns regarding quality of antibodies
  • Challenges associated with epigenetic editing

Case Studies Industry Trends Opportunities

• Emerging applications of epigenetics
• Integration of multi-omics

COMPANY PROFILES

• THERMO FISHER SCIENTIFIC INC.
• ILLUMINA, INC.
• MERCK KGAA
• DANAHER CORPORATION
• BIO-RAD LABORATORIES, INC.
• REVVITY
• PACBIO
• ACTIVE MOTIF, INC.
• NEW ENGLAND BIOLABS
• QIAGEN
• ZYMO RESEARCH CORPORATION
• HOLOGIC DIAGENODE
• F. HOFFMANN-LA ROCHE LTD.
• PROMEGA CORPORATION
• EPIGENTEK GROUP INC.
• EPICYPHER
• FIOS GENOMICS
• GENOMESCAN
• CREATIVE BIOGENE
• BPS BIOSCIENCE, INC.
• ABNOVA CORPORATION
• CREATIVE DIAGNOSTICS
• BIOMODAL
• 10X GENOMICS
• NOVOGENE CO., LTD.

For more information about this report visit https://www.researchandmarkets.com/r/akjxav

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.